Uppsala University Hospital

Verified siteinfo

Sweden Akademiska Sjukhuset Ingang 86 B16, Pet Centrum, 751 85 Uppsala, Sweden

142 trials recruiting
Acute myeloid leukaemia · Breast cancer · Chronic kidney disease
Adults and children

About Specializations

Uppsala University Hospital in Uppsala, Sweden specialises in clinical trials of conditions such as Acute myeloid leukaemia, Breast cancer, Chronic kidney disease, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases at Uppsala University Hospital

Clinical research at this hospital is centered on cardiovascular disease, with a strong focus on pulmonary arterial hypertension and related forms of the condition. The studies are designed to assess whether new treatments can improve symptoms, circulation, and overall disease control.

Study of pulmonary arterial hypertension across idiopathic, heritable, drug- and toxin-induced, connective tissue disease-related, HIV-associated, and congenital heart disease-related cases
Evaluation of a new therapy aimed at improving pulmonary vascular resistance and exercise capacity
Research focused on treatment effectiveness and safety in people living with serious heart-lung conditions

The site brings together a large investigator team to advance better care for patients with complex pulmonary hypertension and to support more effective treatment options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Akademiska Sjukhuset Ingang 86 B16, Pet Centrum751 85 UppsalaSweden

Open in maps ↗

Recruiting now: 142 trials
Conditions studied: 226
Partner status: Verified site

More sites in Uppsala Sweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

291 clinical trials

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Contraception+1

Recruiting

Contraceptive efficacy, safety and tolerability of drospirenone 4 mg (LPRI‑CF113) in healthy women of reproductive age over 13 cycles

InvestigationalNo placebo

Contraceptive efficacy, safety and tolerability of drospirenone 4 mg (LPRI‑CF113) in healthy women of reproductive age over 13 cycles

InvestigationalNo placebo

Sweden

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Drospirenone
Sponsor:Chemo Research S.L.

Contact Research Centre

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational

Sweden

Participants:0–17 years · 18–64 years · 65+ years
Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational

Sweden

Participants:0–17 years · 18–64 years · 65+ years
Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Sweden

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Gastrointestinal carcinoma

Recruiting

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:GSK5764227
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational